Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanghai Yu

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituentsLi Ben, Eric Dale Jones, Enkun Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agentsBen Li, Eric Dale Jones, Enkun Zhou, et al.
Cancer Research|August 23, 2014
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regressionShaomeng Wang, Wei Sun, Yujun Zhao, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituentsLi Ben, Eric Dale Jones, Enkun Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agentsBen Li, Eric Dale Jones, Enkun Zhou, et al.
Cancer Research|August 23, 2014
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regressionShaomeng Wang, Wei Sun, Yujun Zhao, et al.
Pageof 2